Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
Regencell Bioscience Holdings Limited (NASDAQ: RGC) has announced a joint venture with Honor Epic Enterprises to provide Traditional Chinese Medicine (TCM) treatments for COVID-19 in several regions including ASEAN countries, India, Japan, Australia, and New Zealand. Regencell will own 60% of the venture. Initial treatments have shown improvements in 12 COVID patients after about 5 days. While the research is ongoing, the company highlights potential risks and uncertainties surrounding the treatment's commercialization.
- Joint venture established with Honor Epic Enterprises for COVID treatment.
- Regencell owns 60% of the joint venture, allowing significant influence.
- Initial treatments have shown improvements in 12 COVID patients.
- Research and commercialization of COVID treatment are uncertain.
- Potential risks related to the spread of COVID-19 could impact operations.
As COVID vaccination rates in the Asian region are low and COVID infections and deaths rates are rising rapidly, there is a pressing need for a COVID treatment that can be widely available and easily accessible. Since
Regencell HK and Honor Epic plan to work together to make this treatment available in the
The research of JV in COVID treatment is highly uncertain and Regencell cannot guarantee timing of completion of this research and commercialization of COVID treatment in any countries. Regencell will be posting updates regarding treatments in the fight against COVID on its website https://www.regencellbioscience.com/ soon.
About
About
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. Such forward-looking statements include the business plan of the joint venture, objectives, expectations and intentions of the joint venture parties, and Regencell’s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty about the spread of the COVID-19 virus and the impact it will have on expected operations of the joint venture, the demand for the planned COVID TCM treatments. These and other risks and uncertainties are detailed in the other public filings with the
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005415/en/
Corporate:
COO & CSO
ir@rgcbio.com
Investors outside of
Vice President
(212) 836-9611
lcati@equityny.com
Investors in
SPRG_Regencell@sprg.com.hk
Source:
FAQ
What is the joint venture announced by Regencell Bioscience Holdings Limited?
What percentage of the joint venture does Regencell own?
What regions will the COVID-19 treatment be offered?
What have initial patient results shown for the COVID treatment?